These recommendations align with recently published Canadian best practices for the management of patients with advanced G/GEJ adenocarcinoma and allow for the identification of patients who can benefit from anti-HER2 therapies, immune checkpoint inhibitors (ICIs), and TRK inhibitors [6]. Here, ERBB2 is linked to adenocarcinoma.